UNSPSC 51332813: Oxaflumazine

This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0ME957NZRY. European Medicines Agency schedules Oxaflumazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09487MIG. Oxaflumazine generally arises in the molecular formula C26H32F3N3O2S.

UNSPSC 51332813 Oxaflumazine is a Commodity code with minimal alignment between its nominal scope and current state and local procurement activity. The recent opportunities tagged under this code reflect purchases of naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products—none of which are oxaflumazine specifically. State and local governments are using this code to solicit health and safety supplies, including opioid antagonists and pharmacy benefit management services, but the code's name does not accurately reflect the actual buying patterns in the posted opportunities. The issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas HHS Commission), and cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon).

Recent activity spans Florida, Texas, and Minnesota-led cooperative membership. Seminole County released IFB 60459723LAS on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with bids due July 26, 2023; the county required electronic submission through its e-Procurement Portal and set a two-year initial term with optional one-year renewal. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capacity outside traditional pharmacy benefit manager arrangements. MMCAP released an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring vendors to work with three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards; MMCAP reserved the right to make sole, dual, or multi-awards and assessed proposals on fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), administrative-fee agreement (5 percent), and price competitiveness (75 percent). The code shows no explicit set-aside designations in any of the three opportunities.